Avishay Spitzer

Dr. Avishay Spitzer

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Nature
Verified
Journal Article
Closed access
PDF file
AGAvishai Gavish
Avishai Gavish
MTMichael Tyler
Michael Tyler
AGAlissa C. Greenwald
Alissa C. Greenwald
RHRouven Hoefflin
Rouven Hoefflin
DSDor Simkin
Dor Simkin
ITItay Tirosh
Itay Tirosh

1 November 2023 in Nature
Verified
Journal Article
Open access
PDF file
KTKathryn R. Taylor
Kathryn R. Taylor
TBTara Barron
Tara Barron
AHAlexa Hui
Alexa Hui
ASAvishay Spitzer
Avishay Spitzer
BYBelgin Yalçin
Belgin Yalçin
MMMichelle Monje
Michelle Monje
The role of the nervous system in the regulation of cancer is increasingly appreciated. In gliomas, neuronal activity drives tumour progression through paracrine signalling factors such as neuroligin-3 and brain-derived neurotrophic factor1–3 (BDNF), and also through electrophysiologically functional neuron-to-glioma synapses mediated by AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors4,5. The consequent glioma cell membrane depolarization drives tumour proliferation4,6. In the healthy brain, activity-regulated secretion of BDNF promotes adaptive plasticity of synaptic connectivity7,8 and strength9–15. Here we show that malignant synapses exhibit similar plasticity regulated by BDNF. Signalling through the receptor tropomyosin-related kinase B16 (TrkB) to CAMKII, BDNF promotes AMPA receptor trafficking to the glioma cell membrane, resulting in increased amplitude of glutamate-evoked currents in the malignant cells. Linking plasticity of glioma synaptic strength to tumour growth, graded optogenetic control of glioma membrane potential demonstrates that greater depolarizing current amplitude promotes increased glioma proliferation. This potentiation of malignant synaptic strength shares mechanistic features with synaptic plasticity17–22 that contributes to memory and learning in the healthy brain23–26. BDNF–TrkB signalling also regulates the number of neuron-to-glioma synapses. Abrogation of activity-regulated BDNF secretion from the brain microenvironment or loss of glioma TrkB expression robustly inhibits tumour progression. Blocking TrkB genetically or pharmacologically abrogates these effects of BDNF on glioma synapses and substantially prolongs survival in xenograft models of paediatric glioblastoma and diffuse intrinsic pontine glioma. Together, these findings indicate that BDNF–TrkB signalling promotes malignant synaptic plasticity and augments tumour progression.

4 April 2024 in Cancer Cell
Verified
Journal Article
Open access
ASAvishay Spitzer
Avishay Spitzer
SGSimon Gritsch
Simon Gritsch
MNMasashi Nomura
Masashi Nomura
AJAlexander Jucht
Alexander Jucht
JFJerome Fortin
Jerome Fortin
ITItay Tirosh
Itay Tirosh
A subset of patients with IDH-mutant glioma respond to inhibitors of mutant IDH (IDHi), yet the molecular underpinnings of such responses are not understood. Here, we profiled by single-cell or single-nucleus RNA-sequencing three IDH-mutant oligodendrogliomas from patients who derived clinical benefit from IDHi. Importantly, the tissues were sampled on-drug, four weeks from treatment initiation. We further integrate our findings with analysis of single-cell and bulk transcriptomes from independent cohorts and experimental models. We find that IDHi treatment induces a robust differentiation toward the astrocytic lineage, accompanied by a depletion of stem-like cells and a reduction of cell proliferation. Furthermore, mutations in NOTCH1 are associated with decreased astrocytic differentiation and may limit the response to IDHi. Our study highlights the differentiating potential of IDHi on the cellular hierarchies that drive oligodendrogliomas and suggests a genetic modifier that may improve patient stratification.

3 June 2026 in Nature
Verified
Journal Article
Open access
PDF file
KJKevin C. Johnson
Kevin C. Johnson
ASAvishay Spitzer
Avishay Spitzer
FVFrederick Varn
Frederick Varn
MNMasashi Nomura
Masashi Nomura
LGLuciano Garofano
Luciano Garofano
RVRoel G. W. Verhaak
Roel G. W. Verhaak
Gliomas with mutant isocitrate dehydrogenase (IDH) are malignant brain tumours that typically arise in early to mid-adulthood and nearly always recur following treatment 1,2 . However, the genetic and cellular-state changes that drive IDH-mutant glioma progression under treatment remain incompletely understood. Here we integrated single-nucleus transcriptomic profiles, chromatin accessibility profiles and bulk DNA and RNA sequencing from 75 temporally separated gliomas across 35 patients comprising both the oligodendroglioma and astrocytoma IDH-mutant glioma tumour types. We show that malignant cell states transcriptionally resemble stages of normal glial–neuronal lineage development or a reactive mesenchymal-like state, mirroring states previously described in IDH wild-type glioblastoma 3,4 . Malignant cell states displayed distinct chromatin accessibility profiles that were comparable between both IDH-mutant glioma types. The abundance of less differentiated malignant cells increased with grade and with genetic alterations such as PDGFRA amplification. Longitudinal analysis highlighted two major malignant cell-state transition patterns. First, reduced lineage differentiation and increased proliferative malignant cells at recurrence were enriched in gliomas that acquired recurrence-associated genetic events. These included treatment-associated hypermutation, increased copy number changes and cell cycle alterations. Second, increased mesenchymal-like-state abundance occurred independently of acquired genetic alterations and instead coincided with elevated macrophage expression. Overall, our findings provide an integrative model that traces the cell intrinsic and extrinsic factors that shape cellular states during IDH-mutant glioma disease progression.

17 March 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRony Chanoch-Myers
Rony Chanoch-Myers
THToshiro Hara
Toshiro Hara
AGAlissa C. Greenwald
Alissa C. Greenwald
RHRouven Hoefflin
Rouven Hoefflin
LBLillian Bussema
Lillian Bussema
ITItay Tirosh
Itay Tirosh
Glioblastoma invasion into brain parenchyma presents significant challenges for treatment but remains poorly understood. In this study, we combine single-cell RNA sequencing, spatial transcriptomics, and multiplexed imaging of orthotopic xenograft models to investigate glioblastoma invasion. We first screen 20 patient-derived gliomasphere models for their distal (i.e., extending to the contralateral hemisphere) and local invasive potential in mice. We show that models with distal invasion potential are enriched with oligodendrocyte progenitor-like cells, while models with only local invasion potential are enriched with mesenchymal-like cells. These patterns reflect predominantly peri-axonal vs peri-vascular invasion routes, respectively. Next, we analyze the transcriptomes of invading cells within models (compared to tumor core) and identify programs associated with distal and local invasion. Thus, we decouple transcriptional features associated with invasion potential from those associated with the process of invasion. We validate our findings by spatial transcriptomics and multiplexed imaging, further describing the spatial niche of invasive cells. Taken together, our results provide a blueprint for the invasive potential of glioblastoma cell states and of the programs associated with invasion across different scales.

31 January 2025 in Neuro-Oncology
Verified
Journal Article
Open access
IGInbal Greenberg
Inbal Greenberg
FKFayhaa Khair-Dabour
Fayhaa Khair-Dabour
KMKeren Merenbakh-Lamin
Keren Merenbakh-Lamin
ESEthan S Sokol
Ethan S Sokol
AGAnat Klein Goldberg
Anat Klein Goldberg
TRTami Rubinek
Tami Rubinek
Background: Colorectal cancer (CRC) ranks as the fourth most common cause of brain metastasis (BM), with its incidence on the rise. However, the molecular mechanisms driving the formation of these lesions from CRC remain unclear. Methods: We analyzed the Foundation Medicine genomic database, which includes over 35,000 CRC samples from both local and metastatic sites. The role of insulin receptor substrate 2 (IRS2) in CRC brain tropism was investigated using various in vitro (co-culture systems and 3D sphere formation assays), in vivo (intracranial and subcutaneous mouse models), and ex vivo (CRC Patient-Derived Explants) models. The molecular and metabolic effects of IRS2 were examined through RNA sequencing and Seahorse analysis. The therapeutic potential of a combined treatment with NT219, an IRS2 inhibitor, and 5-fluorouracil (5-FU) was assessed using our CRC BM mouse model. Results: Our research reveals a distinctive genomic profile of CRC BM and highlights the role of IRS2 in promoting CRC BM. IRS2 mediates its effect by modulating the β-catenin and oxidative phosphorylation (OXPHOS) pathways. We developed a mouse model of BM from CRC and demonstrated that treatment with the IRS2 inhibitor NT219, in combination with 5-FU, significantly suppresses BM development and prolongs survival. Conclusions: Our work underscores the unique role of IRS2 in facilitating CRC brain adaptation and suggests a novel therapeutic strategy for CRC patients with BM.